Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosilate vs etomidate for hemodynamic stability during induction of general anesthesia in cardiac valve surgery
ChiCTR2100052535Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in Cardiac valve disease (VHD) (3 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoints: Change in mean arterial pressure (MAP) during induction of general anesthesia, Change in heart rate (HR) during induction of general anesthesia and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR2100052535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052535.